Wedbush analyst David Nierengarten downgraded Magenta Therapeutics to Neutral from Outperform.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MGTA:
- Magenta Therapeutics pauses MGTA-117 trial following Grade 5 SAE
- Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
- Magenta Therapeutics price target lowered to $3 from $6 at BTIG
- Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
- Magenta stops dosing participants at Cohort 4 level in MGTA-117 Phase 1/2 trial